Invention Grant
- Patent Title: 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
-
Application No.: US15128051Application Date: 2015-04-02
-
Publication No.: US10233170B2Publication Date: 2019-03-19
- Inventor: Rajinder Singh , Somasekhar Bhamidipati , Pingyu Ding , Donald Payan , Marina Gelman , Todd Kinsella
- Applicant: Rigel Pharmaceuticals, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Rigel Pharmaceuticals, Inc.
- Current Assignee: Rigel Pharmaceuticals, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Agent Travis Young
- International Application: PCT/US2015/024146 WO 20150402
- International Announcement: WO2015/157093 WO 20151015
- Main IPC: C07D401/04
- IPC: C07D401/04 ; A61K31/519 ; A61K45/06 ; A61K31/4439 ; C07D405/14 ; C07F7/08 ; C07K16/28 ; A61K31/444 ; A61K31/517 ; A61K31/695 ; A61K31/5377 ; A61K31/635 ; A61K39/395 ; C07D401/14 ; C07D487/04 ; C07D471/04 ; C07D417/14 ; C07D417/04 ; A61K39/00
Abstract:
The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.
Public/Granted literature
- US20170096409A1 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use Public/Granted day:2017-04-06
Information query
